SCHEMBL10235403

SCHEMBL10235403

CCc1cnn2cc(-c3ccnc(Cl)c3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
BMP4 P12644 1/20 0.37
METAP2 P50579 1/20 0.36
ACVR2A P27037 2/20 0.35
TGFBR2 P37173 2/20 0.35
TGFBR1 P36897 1/20 0.35
IDO1 P14902 1/20 0.35
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
MAPK14 Q16539 2/20 0.33
CHRM1 P11229 1/20 0.33
PARP10 Q53GL7 1/20 0.33
PARP11 Q9NR21 1/20 0.33
WNT3A P56704 1/20 0.33
KDR P35968 1/20 0.33
RET P07949 1/20 0.32
CYP19A1 P11511 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10234136 0.84 JAK1 (0.40) JAK1JAK3BMP4ACVR2ATGFBR2
SCHEMBL10233441 0.82 ACVR2A (0.53) JAK1JAK3BMP4ACVR2ATGFBR2
SCHEMBL10183057 0.79 BMP4 (0.37) JAK1JAK3BMP4METAP2IDO1
SCHEMBL10233668 0.75 PIK3CG (0.40) JAK1JAK3KDRRET
SCHEMBL10234979 0.74 JAK1 (0.38) JAK1JAK3MAPK14KDRRET
SCHEMBL25099101 0.74 EPHB3 (0.43)
SCHEMBL10235432 0.72 JAK1 (0.39) JAK1JAK3PARP10PARP11
SCHEMBL18179504 0.71 MAPK14 (0.44) IDO1CCNCCDK8MAPK14PARP10
SCHEMBL14071529 0.69 RECQL (0.44) IDO1CCNCCDK8MAPK14WNT3A
SCHEMBL23425908 0.69 EPHB3 (0.42) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF JAK1 941/4885JAK3 853/4885BMP4 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.